| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
70,650,000 |
| Market
Cap: |
3.90(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$38.62 - $89.12 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CRISPR Therapeutics is a gene editing company focused on the development of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) based therapeutics. CRISPR/Cas9 is a technology for gene editing, the process of altering specific sequences of genomic DNA. Co. is developing several gene-edited allogeneic cell therapy programs. Co.'s main product candidate, CTX001, is an investigational ex vivo CRISPR gene-edited therapy that is being evaluated for patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce fetal hemoglobin in red blood cells.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
61,438 |
159,721 |
184,721 |
409,721 |
| Total Sell Value |
$4,291,798 |
$10,834,513 |
$12,456,407 |
$25,314,056 |
| Total People Sold |
3 |
3 |
3 |
3 |
| Total Sell Transactions |
7 |
12 |
13 |
22 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Woiwode Thomas |
Director |
– • – |
2016-10-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
239,648 |
|
- |
|
| Woiwode Thomas |
Director |
– • – |
2016-10-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
342,007 |
|
- |
|
| Lundberg Sven Ante |
Chief Scientific OfficerOffice |
• – – |
2016-10-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
55,217 |
|
- |
|
| Lundberg Sven Ante |
Chief Scientific OfficerOffice |
• – – |
2016-10-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
450,000 |
|
- |
|
| Kulkarni Samarth |
Chief Business OfficerOfficer |
• – – |
2016-10-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
134,047 |
|
- |
|
| Versant Ophthalmic Affiliates I, L.p. |
10% Owner |
– – • |
2016-10-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
239,648 |
|
- |
|
| Novak Rodger |
Chief Executive OfficerOfficer |
• • – |
2016-10-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,215,005 |
|
- |
|
| Dylan-Hyde Tyler |
Chief Legal OfficerOfficer |
• – – |
2016-10-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
205,204 |
|
- |
|
483 Records found
|
|
Page 20 of 20 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.49 (0.88%) 
